@article {42, editor = {,}, title = {Once-daily triple therapy inhaler for COPD}, volume = {56}, number = {4}, pages = {42--45}, year = {2018}, doi = {10.1136/dtb.2018.4.0611}, publisher = {British Medical Journal Publishing Group}, abstract = {â–¼Trelegy Ellipta (GSK) is a dry powder inhaler containing fluticasone furoate (inhaled corticosteroid [ICS]), vilanterol trifenatate (long-acting beta2 agonist [LABA]) and umeclidinium bromide (long-acting muscarinic antagonist [LAMA]).1 It is licensed for once-daily use as maintenance treatment for adults with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA. Here, we consider the evidence for this combination product and discuss how it fits with current management strategies.}, issn = {0012-6543}, URL = {https://dtb.bmj.com/content/56/4/42}, eprint = {https://dtb.bmj.com/content/56/4/42.full.pdf}, journal = {Drug and Therapeutics Bulletin} }